Axsome Therapeutics AXSM Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 92.6%0.0pp | 92.6%+0.7pp | 91.9%+0.4pp | 91.5%0.0pp | 91.5%+0.1pp | |
| Operating margin | -24.4%+1.7pp | -26.1%+11.7pp | -37.8%+8.4pp | -46.2%+16.3pp | -62.5%+10.2pp | |
| Net margin | -26.6%+2.1pp | -28.7%+12.2pp | -40.9%+9.0pp | -49.9%+14.5pp | -64.4%+10.1pp | |
| EBITDA margin | -23.5%+1.6pp | -25%+11.6pp | -36.6%+8.2pp | -44.9%+16.1pp | -60.9%+10.0pp | |
| Free cash flow margin | -10.2%+4.7pp | -14.9%+3.4pp | -18.2%+6.2pp | -24.5%+3.0pp | -27.5%+5.9pp | |
| Returns | ||||||
| Return on equity | -349.4%-97.3pp | -252.1%+23.4pp | -275.5%+5.2pp | -280.7%+1.5pp | -282.2%-50.5pp | |
| Return on assets | -28.7%+0.4pp | -29.1%+8.2pp | -37.3%+4.3pp | -41.6%+7.2pp | -48.7%+0.9pp | |
| Efficiency | ||||||
| Asset turnover | 1.1×+0.1× | 1×+0.1× | 0.9×+0.1× | 0.8×+0.1× | 0.8×+0.1× | |
| Inventory turnover | 2.2×0.0× | 2.2×-0.2× | 2.4×-0.1× | 2.5×+0.2× | 2.3×+0.1× | |
| Liquidity | ||||||
| Current ratio | 1.4×-0.2× | 1.6×0.0× | 1.6×0.0× | 1.6×-0.5× | 2×-0.1× | |
| Quick ratio | 1.3×-0.2× | 1.5×0.0× | 1.5×0.0× | 1.5×-0.4× | 2×-0.1× | |
| Cash ratio | 0.7×-0.2× | 0.9×-0.1× | 0.9×0.0× | 0.9×-0.3× | 1.2×-0.1× | |
| Leverage | ||||||
| Debt-to-equity | 4×+1.6× | 2.5×-0.5× | 3×0.0× | 3×-1.0× | 4×+0.6× | |
| Debt-to-assets | 0.3×0.0× | 0.3×0.0× | 0.3×0.0× | 0.3×0.0× | 0.4×0.0× | |
| Per Share | ||||||
| Book value per share | $1.07-39.9% | $1.77+20.4% | $1.47-0.3% | $1.48+35.8% | $1.09-8.5% | |
| Valuation | ||||||
| Market capitalization | $8.65B-6.1% | $9.21B+51.9% | $6.06B+18.1% | $5.13B-9.7% | $5.69B+38.7% | |
| Enterprise value | $8.56B-6.0% | $9.1B+52.9% | $5.95B+18.0% | $5.05B-9.8% | $5.6B+40.7% | |
| Price / sales | 12.2×-2.2× | 14.4×+3.6× | 10.8×+0.4× | 10.4×-2.8× | 13.2×+2.5× | |
| Price / book | 158.4×+54.1× | 104.3×+22.1× | 82.2×+12.0× | 70.2×-36.6× | 106.9×+35.0× | |
| EV / sales | 12.1×-2.2× | 14.3×+3.6× | 10.6×+0.4× | 10.2×-2.8× | 13×+2.6× | |
| Free cash flow yield | -0.8%+0.2pp | -1%+0.7pp | -1.7%+0.7pp | -2.4%-0.3pp | -2.1%+1.0pp | |
| Earnings yield | -2.2%-0.2pp | -2%+1.8pp | -3.8%+1.0pp | -4.8%+0.1pp | -4.9%+2.1pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Axsome Therapeutics's profit margins?
- Axsome Therapeutics (AXSM) runs a 92.6% gross margin and a -24.4% operating margin, with a -26.6% net margin.
- Where do Axsome Therapeutics's ratios come from?
- Every ratio is computed from Axsome Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
